Kailera Therapeutics (KLRA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $11.25, -3.93% vs the prior close of $11.71.
- Volume 1.30M shares, 1.2x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
KLRA slides 3.9% to $11.25. Closed at $11.25, -3.93% vs the prior close of $11.71. Day range $11.18–$11.78, opened at $11.75.
KLRA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — KLRA slides 3.9% to $11.25
- Closed at $11.25, -3.93% vs the prior close of $11.71. Day range $11.18–$11.78, opened at $11.75.
- Volume was 1.30M shares, 1.2x its 50-day average of 1.07M.
- Price is -21.7% vs its 50-day average ($14.38).
- 52-week range $9.76–$28.23; today's close sits at 8% of that range, 60.1% below the 52-week high.
Oct 15, 2026 — KLRA jumps 9.0% to $11.71
- Closed at $11.71, +9.03% vs the prior close of $10.74. Day range $10.50–$11.76, opened at $10.61.
- Volume was 1.17M shares, 1.1x its 50-day average of 1.05M.
- Price is -19.4% vs its 50-day average ($14.53).
- 52-week range $9.76–$28.23; today's close sits at 11% of that range, 58.5% below the 52-week high.
Oct 14, 2026 — KLRA ends flat (-0.3%) to $10.74, 3 down days in a row
- Closed at $10.74, -0.28% vs the prior close of $10.77. Day range $10.44–$10.99, opened at $10.64.
- Volume was 1.30M shares, 1.3x its 50-day average of 1.03M.
- Price is -26.7% vs its 50-day average ($14.66).
- 52-week range $9.76–$28.23; today's close sits at 5% of that range, 62.0% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — KLRA slides 4.9% to $10.77
- Closed at $10.77, -4.94% vs the prior close of $11.33. Day range $10.72–$11.44, opened at $11.31.
- Volume was 1.11M shares, 1.1x its 50-day average of 1.01M.
- Price is -27.3% vs its 50-day average ($14.81).
- 52-week range $9.76–$28.23; today's close sits at 5% of that range, 61.8% below the 52-week high.
Oct 12, 2026 — KLRA dips 2.4% to $11.33
- Closed at $11.33, -2.41% vs the prior close of $11.61. Day range $10.98–$11.70, opened at $11.39.
- Volume was 1.22M shares, 1.2x its 50-day average of 998.63K.
- Price is -24.1% vs its 50-day average ($14.94).
- 52-week range $9.76–$28.23; today's close sits at 9% of that range, 59.9% below the 52-week high.
Oct 9, 2026 — KLRA jumps 16.1% to $11.61 on 2.3x normal volume
- Closed at $11.61, +16.10% vs the prior close of $10.00. Day range $9.98–$11.81, opened at $10.13.
- Volume was 2.18M shares, 2.3x its 50-day average of 966.38K — unusually heavy trading.
- Price is -22.9% vs its 50-day average ($15.05).
- 52-week range $9.76–$28.23; today's close sits at 10% of that range, 58.9% below the 52-week high.
Oct 8, 2026 — KLRA slides 5.0% to $10.00, a 6-month low, 3 down days in a row
- Closed at $10.00, -5.03% vs the prior close of $10.53. Day range $9.76–$10.42, opened at $10.42.
- Volume was 1.53M shares, 1.6x its 50-day average of 946.27K.
- Price is -34.0% vs its 50-day average ($15.16).
- 52-week range $9.76–$28.23; today's close sits at 1% of that range, 64.6% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — KLRA dips 2.8% to $10.53
- Closed at $10.53, -2.77% vs the prior close of $10.83. Day range $10.50–$11.12, opened at $10.77.
- Volume was 1.09M shares, 1.2x its 50-day average of 935.23K.
- Price is -31.2% vs its 50-day average ($15.30).
- 52-week range $9.85–$28.23; today's close sits at 4% of that range, 62.7% below the 52-week high.
Oct 6, 2026 — KLRA ends flat (-0.1%) to $10.83
- Closed at $10.83, -0.09% vs the prior close of $10.84. Day range $10.32–$11.24, opened at $10.95.
- Volume was 1.45M shares, 1.6x its 50-day average of 917.54K.
- Price is -29.8% vs its 50-day average ($15.42).
- 52-week range $9.85–$28.23; today's close sits at 5% of that range, 61.6% below the 52-week high.
Oct 5, 2026 — KLRA jumps 4.3% to $10.84 on 2.0x normal volume
- Closed at $10.84, +4.33% vs the prior close of $10.39. Day range $9.85–$11.04, opened at $10.48.
- Volume was 1.81M shares, 2.0x its 50-day average of 894.76K — unusually heavy trading.
- Price is -30.3% vs its 50-day average ($15.55).
- 52-week range $9.85–$28.23; today's close sits at 5% of that range, 61.6% below the 52-week high.
Oct 2, 2026 — KLRA slides 5.8% to $10.39, a 6-month low
- Closed at $10.39, -5.80% vs the prior close of $11.03. Day range $10.29–$11.40, opened at $11.23.
- Volume was 1.28M shares, 1.5x its 50-day average of 881.33K.
- Price is -33.8% vs its 50-day average ($15.69).
- 52-week range $10.29–$28.23; today's close sits at 1% of that range, 63.2% below the 52-week high.
KLRA latest news & SEC filings
Every SEC filing by or about KLRA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 9, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$111.31M (prior year -$28.95M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.09 (prior year -$28947.00) (loss narrowed vs Jun 30, 2025)
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 5, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 8, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Things to know before you trade KLRA
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: May 26, 2026. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.75% (largest 16.1%). That is a volatile stock.
- Liquidity: about 1.48M shares (≈$16.61M) trade per day on average.
- 52-week position: $11.25 vs a range of $9.76–$28.23 (8% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Investments, Lp Rtw bought 500,000 shares on Apr 20, 2026.
- Latest filings: 10-Q Aug 12, 2026; 8-K Aug 12, 2026; 10-Q May 26, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
KLRA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 11.75 | 11.78 | 11.18 | 11.25 | 1.30M |
| Oct 15, 2026 | 10.61 | 11.76 | 10.50 | 11.71 | 1.17M |
| Oct 14, 2026 | 10.64 | 10.99 | 10.44 | 10.74 | 1.30M |
| Oct 13, 2026 | 11.31 | 11.44 | 10.72 | 10.77 | 1.11M |
| Oct 12, 2026 | 11.39 | 11.70 | 10.98 | 11.33 | 1.22M |
| Oct 9, 2026 | 10.13 | 11.81 | 9.98 | 11.61 | 2.18M |
| Oct 8, 2026 | 10.42 | 10.42 | 9.76 | 10.00 | 1.53M |
| Oct 7, 2026 | 10.77 | 11.12 | 10.50 | 10.53 | 1.09M |
| Oct 6, 2026 | 10.95 | 11.24 | 10.32 | 10.83 | 1.45M |
| Oct 5, 2026 | 10.48 | 11.04 | 9.85 | 10.84 | 1.81M |
| Oct 2, 2026 | 11.23 | 11.40 | 10.29 | 10.39 | 1.28M |
| Oct 1, 2026 | 11.39 | 11.76 | 10.57 | 11.03 | 2.19M |
| Sep 30, 2026 | 11.16 | 11.67 | 10.86 | 11.42 | 1.37M |
| Sep 29, 2026 | 11.10 | 11.31 | 10.83 | 10.99 | 694.10K |
| Sep 28, 2026 | 11.30 | 11.52 | 11.07 | 11.12 | 1.43M |
| Sep 25, 2026 | 11.80 | 12.33 | 11.10 | 11.22 | 1.72M |
| Sep 24, 2026 | 12.85 | 13.12 | 11.77 | 11.98 | 2.76M |
| Sep 23, 2026 | 12.76 | 13.22 | 12.56 | 13.13 | 1.63M |
| Sep 22, 2026 | 12.46 | 12.95 | 12.05 | 12.79 | 1.23M |
| Sep 21, 2026 | 12.95 | 13.04 | 11.84 | 11.99 | 1.05M |
About Kailera Therapeutics
Kailera Therapeutics (KLRA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WALTHAM, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 2096997.
KLRA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Frank Clyburn | Director | Apr 20, 2026 |
| Christopher Hite | Director | Apr 20, 2026 |
| Andrew T. Kaplan | Director | Apr 20, 2026 |
| Adam Koppel | Director | Apr 20, 2026 |
| Yuting Liu | Director | Apr 16, 2026 |
| Martin Mackay | Director | Apr 20, 2026 |
| John F Milligan | Director | Apr 20, 2026 |
| Ronald C Jr Renaud | CEO & President | Jun 11, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Scott Akamine | Chief Legal Officer | Apr 20, 2026 |
| Paul D. Burgess | See Remarks | Apr 20, 2026 |
| Paula Cloghessy | Chief People Officer | Apr 20, 2026 |
| Jamie Beth Coleman | Chief Commercial Officer | Apr 20, 2026 |
| Nur Nicholson | Chief Technology Officer | Sep 9, 2026 |
| Douglas W. Pagan | Chief Financial Officer | Apr 20, 2026 |
| Ronald C Jr Renaud | CEO & President | Jun 11, 2026 |
| Kathleen Tregoning | See Remarks | Jul 8, 2026 |
| Scott M. Wasserman | Chief Medical Officer | Apr 20, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Apr 20, 2026 | Investments, Lp Rtw | Buy | 500,000 | $16.00 |
| Apr 20, 2026 | Investments, Lp Rtw | Buy | 500,000 | $16.00 |
| Apr 20, 2026 | Roderick Wong | Buy | 500,000 | $16.00 |
| Apr 20, 2026 | Roderick Wong | Buy | 500,000 | $16.00 |
| Apr 20, 2026 | Investments, Lp Rtw | Buy | 500,000 | $16.00 |
| Apr 20, 2026 | Investments, Lp Rtw | Buy | 500,000 | $16.00 |
| Apr 20, 2026 | Roderick Wong | Buy | 500,000 | $16.00 |
| Apr 20, 2026 | Roderick Wong | Buy | 500,000 | $16.00 |
| Apr 20, 2026 | Perseus Investor, Lp Bcpe | Buy | 8,398,438 | $16.00 |
| Apr 20, 2026 | Perseus Investor, Lp Bcpe | Buy | 8,398,438 | $16.00 |
| Apr 20, 2026 | Capital Fund Xiv, L.P. Bain | Buy | 8,398,438 | $16.00 |
| Apr 20, 2026 | Capital Fund Xiv, L.P. Bain | Buy | 8,398,438 | $16.00 |
| Apr 20, 2026 | Capital Xiv General Partner, Llc Bain | Buy | 8,398,438 | $16.00 |
| Apr 20, 2026 | Capital Xiv General Partner, Llc Bain | Buy | 8,398,438 | $16.00 |
| Apr 20, 2026 | Perseus Investor Gp, Llc Bcpe | Buy | 8,398,438 | $16.00 |
KLRA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $1.21B, total liabilities $92.95M, cash $130.30M (as of Jun 30, 2026).
KLRA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $18.59 |
| May 26, 2026 | 8-K Item 2.02 (results) | $21.57 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on KLRA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.